Atai Beckley Inc SEC Filings

Atai Beckley N.V. reported Q3 2025 results showing modest revenue but a larger loss driven by fair value changes and operating costs. Total revenue was $749 thousand, primarily from research and development services. Operating expenses reached $29.2 million (R&D $14.7 million, G&A $14.5 million), leading to a loss from operations of $28.4 million. Other expense was weighed by a $32.6 million net change in fair value of assets and liabilities. Net loss was $61.1 million (basic and diluted loss per share $0.28).

Year‑to‑date, revenue totaled $3.023 million and net loss was $115.3 million. Liquidity improved versus year‑end with $30.4 million in cash and cash equivalents, $84.2 million in securities carried at fair value, and $11.4 million in digital assets. Management states existing cash and short‑term securities as of September 30, 2025 will be sufficient to fund operations for at least the next 12 months from issuance. Financing activities included $118.2 million in equity offering proceeds, $21.5 million from pre‑funded warrants, and elimination of long‑term debt.

As of November 10, 2025, shares outstanding were 363,190,522. The company closed its strategic combination with Beckley Psytech on November 5, 2025 and changed its name to Atai Beckley N.V.

Atai Beckley N.V. (ATAI) furnished an update via Form 8-K, noting it issued a press release announcing financial results for the quarter ended September 30, 2025 and provided corporate and clinical updates. The press release is attached as Exhibit 99.1. The company stated the information under Item 2.02, including Exhibit 99.1, is being furnished and is not deemed filed under Section 18 of the Exchange Act or incorporated by reference unless specifically noted.

Atai Beckley N.V. (ATAI) reported insider activity on November 5, 2025. A director received several stock option grants: three fully vested options at an exercise price of $1.35 covering 456,011, 97,716, and 62,394 common shares with expirations from July 2025 to October 2032, and an additional 103,000 options at $4.48 expiring in November 2035 that vest on the first anniversary of the grant date.

On the same date, the company completed its acquisition of Beckley Psytech Limited, issuing 103,000,066 common shares as consideration or as underlying replacement awards pursuant to the purchase agreement.

Atai Beckley N.V. (ATAI) reported an insider transaction: a director acquired 7,702,990 common shares on November 5, 2025. The filing notes this occurred in connection with the Issuer’s completion of its acquisition of Beckley Psytech, for which an aggregate of 103,000,066 common shares were issued as consideration or as underlying replacement awards.

The director also received two stock option grants with a $4.48 exercise price, covering 103,000 and 40,400 shares, each expiring on November 5, 2035. One option vests in full on the first anniversary of the grant date, and the other vests in 12 substantially equal monthly installments beginning December 5, 2025. Following the transactions, the director held 7,702,990 common shares directly.

Atai Beckley N.V. (ATAI) reported a director’s Form 4 reflecting a new stock option grant. On 11/04/2025, the director was granted 56,818 stock options with an exercise price of $5.28 per share. The option expires on 11/04/2035 and will vest as to 100% of the underlying shares on the first anniversary of the grant date.

Following the reported transaction, the director beneficially owned 56,818 derivative securities, held directly. The filing notes the transaction code “A,” indicating an option grant.

Atai Beckley N.V. (ATAI) reported an insider status update: a director filed a Form 3 for an event dated 11/05/2025.

The filing states no securities are beneficially owned. It was filed by one reporting person, with execution by an attorney-in-fact pursuant to Exhibit 24 (Power of Attorney).

Atai Beckley N.V. (ATAI) insider filing: A director filed an initial Form 3 reflecting their status as a board member as of 11/05/2025. The filing states that no securities are beneficially owned by the reporting person at this time. The form was submitted by attorney-in-fact Ryan Barrett under a Power of Attorney (Exhibit 24). This is an administrative disclosure establishing insider reporting status and current holdings.

Atai Beckley N.V. filed a prospectus supplement covering the resale from time to time by certain selling securityholders of up to 5,316,238 common shares. The registration satisfies rights granted in connection with the Company’s acquisition of the issued share capital of Beckley Psytech Limited not already owned by the Company.

The Company also filed a legal opinion from NautaDutilh N.V. as Exhibit 5.1 regarding the validity of the shares, along with a related consent and the cover page interactive data file.

ATAI Life Sciences filed a prospectus supplement to register for resale up to 5,316,238 common shares previously issued to selling securityholders in connection with the acquisition of Beckley Psytech. The shares may be sold from time to time by the holders using various methods described in the document.

ATAI will not receive proceeds from sales by the selling securityholders, though it will cover certain registration expenses. The shares trade on the Nasdaq Global Market under the symbol ATAI. As context, shares outstanding were 363,114,450 as of November 5, 2025.

The resale registration lists individual holder amounts, including Shlomi Raz 3,268,819 and Cantor Fitzgerald & Co. 900,901. Sales may occur through underwriters, dealers, agents, or direct transactions at market, related, fixed, or negotiated prices.